NTRA (Natera) Other Current Liabilities: $116 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NTRA Natera Inc NTRA
77 GF Score
Price $324.84
GF Value $217.87
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Natera Other Current Liabilities?

Natera NTRA -0.07% 77 Other Current Liabilities is $116 Mil as of Jun. 2026. GuruFocus rates NTRA with a GF Score™ of 77/100 and a GF Value™ of $217.87 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Natera's other current liabilities for the quarter that ended in Jun. 2026 was $116 Mil.

Natera's quarterly other current liabilities increased from Dec. 2025 ($102 Mil) to Mar. 2026 ($153 Mil) but then declined from Mar. 2026 ($153 Mil) to Jun. 2026 ($116 Mil).

Natera's annual other current liabilities increased from Dec. 2023 ($69 Mil) to Dec. 2024 ($73 Mil) and increased from Dec. 2024 ($73 Mil) to Dec. 2025 ($102 Mil).

Natera Other Current Liabilities Related Terms

Natera Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Natera's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Natera Other Current Liabilities Chart

Natera Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 58.15 62.96 69.10 73.39 102.11

Natera Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 64.73 87.55 102.11 153.46 115.58
NTRA
77GF Score
Natera Inc NTRA
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Natera Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $116 Mil mean?
Natera (NTRA) has a Other Current Liabilities of $116 Mil as of Jun. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Natera.
Is Natera's Other Current Liabilities too high?
Natera's current Other Current Liabilities is $116 Mil. Overall, Natera has a GF Score™ of 77/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Natera's Other Current Liabilities compare to WAT and A?
Natera's Other Current Liabilities of $116 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Medical Diagnostics & Research company?
A good Other Current Liabilities depends on the Medical Diagnostics & Research industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Natera. Natera's current Other Current Liabilities is $116 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Natera stock overvalued right now?
Based on GuruFocus' analysis, Natera (NTRA) is currently considered Significantly Overvalued. The stock's GF Value™ is $217.87, compared to a current price of $324.84 — trading 49.1% above its estimated fair value. The current Other Current Liabilities is $116 Mil. Natera's overall GF Score™ is 77/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Natera (NTRA), the current Other Current Liabilities is $116 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Natera (NTRA) Overvalued in 2026?

Based on GuruFocus' analysis, Natera stock appears to be overvalued. The current stock price of $324.84 is trading 49.1% above its estimated GF Value™ of $217.87. GuruFocus considers Natera to be Significantly Overvalued.

Key valuation signals for NTRA:

  • Other Current Liabilities: $116 Mil
  • GF Value™: $217.87 vs. price of $324.84 (49.1% above fair value)
  • GF Score™: 77/100 with 6 warning signs

No single metric tells the full story. See the NTRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Natera Business Description

Other Exchanges NTRA:Mexico45E:Germany
Address 13011 McCallen Pass, Building A Suite 100, Austin, TX, USA, 78753
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
77GF Score

Get the complete analysis for NTRA

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$324.84
Price
$217.87
GF Value